Neoplasm

In this study, SYT-SSX fusion transcripts (SS18-SSX1 and SS18-SSX2) were detected in 29 (64%) and 16 (36%) of the tumors, respectively. There was a significant relationship (P=0.003) between histologi… (full text at CIViC)

PMID 9428816 · Kawai et al., 1998 · Open in CIViC

This study collected data on SYT-SSX fusion type, pathology, and clinical course in a retrospective multi-institutional study of 243 patients (age range, 6-82) with synovial sarcoma. SYT-SSX1 and SYT-… (full text at CIViC)

PMID 11782370 · Ladanyi et al., 2002 · Open in CIViC

Three synovial sarcomas were assayed for SYT-SSX fusion messenger RNA by nested RT-PCR. In a single case an SYT-SSX4 (SS18-SSX4) fusion was detected. The majority of synovial sarcomas are characterize… (full text at CIViC)

PMID 10359553 · Skytting et al., 1999 · Open in CIViC

Patients originated from 4 international (UK, Netherlands, Germany, and US) studies, and included 16 B-cell precursor ALL (B-ALL) patients (aged 2-29 years) with SSBP2-CSF1R fusions arising from diffe… (full text at CIViC)

PMID 33197935 · Schwab et al., 2021 · Open in CIViC

A multicenter, retrospective study that included 1389 consecutively enrolled, newly diagnosed patients with B-lineage acute lymphoblastic leukemia (B-ALL). There were 3 patients that harbored SSPB2-CS… (full text at CIViC)

PMID 28408464 · Reshmi et al., 2017 · Open in CIViC

In this study which included 1389 cases of high-risk pediatric B-ALL, 284 were identified by TaqMan Low Density Array to have a Ph-like gene expression signature. RT-PCR or RNAseq performed on CRLF2 n… (full text at CIViC)

PMID 28408464 · Reshmi et al., 2017 · Open in CIViC

In B-lymphoblastic leukemia/lymphoma (B-ALL), the presence of this fusion is associated with so-called BCR/ABL1 like (Ph-like) subtype of the disease.The SSBP2-JAK2 fusion is rare; In this study invol… (full text at CIViC)

PMID 27870571 · Roberts et al., 2017 · Open in CIViC

Phase II study of pasireotide in metastatic neuroendocrine tumours enrolled 29 patients. Overall median PFS was 11 months (95% CI, 7.6–16 months). High SSTR5 expression (seen in 17/22 samples measured… (full text at CIViC)

PMID 25376618 · Cives et al., 2015 · Open in CIViC

The STAG2 p.His421Thrfs*4 mutation is a truncating frameshift variant located in exon 14 of the STAG2 gene, a core component of the cohesin complex. Truncating mutations in STAG2 are recurrent across … (full text at CIViC)

PMID 22135298 · Hornbeck et al., 2012 · Open in CIViC

In a study of 96 Ewing sarcoma tumors, 15% showed heterogenous loss of STAG2 expression in IHC analysis. Of those with STAG2 expression loss, 88% presented with metastatic disease compared to only 27… (full text at CIViC)

PMID 25186949 · Crompton et al., 2014 · Open in CIViC

Sequencing of 93 secondary acute myeloid leukemias (AML) compared to 180 TCGA de novo AMLs identified STAG2 mutations had >95% sensitivity for being diagnostic of secondary AML, identifying a patient … (full text at CIViC)

PMID 25550361 · Lindsley et al., 2015 · Open in CIViC

Tumor samples from 125 patients with bladder cancer were assessed by IHC for STAG2 expression. STAG2-negativity was associated with lower histological grade (p = 0.009). Complete loss of STAG2 express… (full text at CIViC)

PMID 26838030 · Qiao et al., 2016 · Open in CIViC

A375 melanoma cells containing an inducible shRNA for STAG2 were grown as xenograft tumors in nude mice. The mice in which STAG2 was silenced had tumors that were less sensitive to vemurafenib-induced… (full text at CIViC)

PMID 27500726 · Shen et al., 2016 · Open in CIViC

A375 melanoma cells containing an inducible shRNA for STAG3 were grown as xenograft tumors in nude mice. The mice in which STAG3 was silenced had tumors that were less sensitive to vemurafenib-induced… (full text at CIViC)

PMID 27500726 · Shen et al., 2016 · Open in CIViC

A cohort of 28 patients with malignant melanoma, with previously excised high-risk lesions were evaluated for STAT1 and STAT2 expression prior to treatment with v. interferon-alpha 2b (IFN-a2b). Stain… (full text at CIViC)

PMID 15668815 · Lesinski et al., 2005 · Open in CIViC

Researchers calculated Spearman rank correlation coefficients for each gene vs proliferation rate and platinum drug sensitivity in 14 ovarian cancer cell lines. STAT1 expression was found to be highly… (full text at CIViC)

PMID 15726096 · Roberts et al., 2005 · Open in CIViC

The authors sequenced exons 19–24 of STAT3 (the region where the hot spot has been reported in other malignancies) in 48 diffuse large B-cell lymphoma samples.

PMID 24837465 · Ohgami et al., 2014 · Open in CIViC

Mutations in the Src homology 2 (SH2) domain (exon 21) of STAT3 were found in 31 of 77 patients (40%) with large granular lymphocytic leukemia. Recurrent mutational hot spots included Y640F, D661V, D6… (full text at CIViC)

PMID 22591296 · Koskela et al., 2012 · Open in CIViC

The examination of interferon-resistant melanoma cell lines in relation to STAT5 expression, indicated a correlation between overexpression and resistance to interferon α (IFNα) immunotherapy. From an… (full text at CIViC)

PMID 16169484 · Wellbrock et al., 2005 · Open in CIViC

Meta-analysis of 275 T-cell prolymphocytic leukemia (T-PLL) patients from 10 different studies. Sequencing data from each study (Sanger sequencing, targeted amplicon sequencing, whole exome sequencing… (full text at CIViC)

PMID 31766351 · Wahnschaffe et al., 2019 · Open in CIViC

The authors analyzed exome data from 38 relapsed DLBCLs and 138 diagnostic DLBCLs and identified genes enriched for mutations in the former relative to the latter.

PMID 26647218 · Morin et al., 2016 · Open in CIViC

Case study of a 46-year old male patient with Peutz-Jeghers Syndrome and pancreatic cancer. A germline STK11 D194E mutation was identified with LOH in the tumor sample. phospho-S6 ribosomal protein st… (full text at CIViC)

PMID 21189378 · Klümpen et al., 2011 · Open in CIViC

In a retrospective analysis of 567 non-squamous, non-small cell lung cancer patients, Exon 1-2 mutations in STK11 were significantly associated with shorter OS (24 vs. 69 months) also after multivaria… (full text at CIViC)

PMID 26625312 · Pécuchet et al., 2017 · Open in CIViC

This study analyzed response to treatment of a heavily pre-treated biphenotypic breast carcinoma patient with a mutation in the gene STK11. The STK11 F354L alteration is associated with loss of hetero… (full text at CIViC)

PMID 28550065 · Parachoniak et al., 2017 · Open in CIViC

A clinical trial comparing selumetinib and docetaxel vs. docetaxel and placebo in KRAS mutant NSCLC was recapitulated in mice. Tumors were induced in lung epithelium by nasal instillation of CRE-beari… (full text at CIViC)

PMID 22425996 · Chen et al., 2012 · Open in CIViC

Preclinical study in 5 NSCLC cell lines. Two LKB1 (STK11) mutant cell lines had higher basal levels of mTOR activity (pS6K and p4EBP1 levels) but were not more sensitive to mTOR inhibitors (everolimus… (full text at CIViC)

PMID 26027660 · Xiao et al., 2015 · Open in CIViC

STK11 is mutated and inactivated in 20-30% of non-small cell lung cancers, most often in the adenocarcinoma subtype.

PMID 15021901 · Carretero et al., 2004 · Open in CIViC

STK11 is mutated and inactivated in 20-30% of non-small cell lung cancers, most often in the adenocarcinoma subtype.

PMID 21102257 · Marcus et al., 2010 · Open in CIViC

In a retrospective cohort of stage III NSCLC treated with definitive radiotherapy with or without concurrent chemotherapy (n = 164), somatic STK11 (LKB1) mutations (n = 12) were associated with higher… (full text at CIViC)

PMID 33323404 · Sitthideatphaiboon et al., 2021 · Open in CIViC

A retrospective analysis of 871 non-squamous NSCLC patients treated with chemotherapy (platinum compound plus pemetrexed) combined with immunotherapy (pembrolizumab) found that those with STK11 mutati… (full text at CIViC)

PMID 39385035 · Skoulidis et al., 2024 · Open in CIViC

A retrospective analysis of 871 non-squamous NSCLC patients treated with chemotherapy (platinum compound plus pemetrexed) combined with immunotherapy (pembrolizumab) found that those with STK11 or KEA… (full text at CIViC)

PMID 39385035 · Skoulidis et al., 2024 · Open in CIViC

In a case report of KRAS wild‑type NSCLC (n = 1, age 53 male) a tumor harbored concurrent STK11 (rearrangement exon 1) and KEAP1 (G417W) mutations, along with additional somatic alterations (including… (full text at CIViC)

PMID 36858519 · Sumii et al., 2023 · Open in CIViC

STK11-deficient cells were sensitive to treatment with MAPK11 inhibitor SB202190.

PMID 26391455 · Grossi et al., 2015 · Open in CIViC

33 patients were retrospectively analyzed for Stathmin expression by IHC. High protein expression was correlated with poor response to paclitaxel but not other chemotherapy. The authors supported this… (full text at CIViC)

PMID 24587245 · Werner et al., 2014 · Open in CIViC